Be warned, big capital raise is coming. Now that this company is...

Be warned, big capital raise is coming. Now that this company is getting close to starting their Phase I/II clinical study (which by the way is a very early human study unlike a Phase III - so this company could be a decade away from commercialisation - if they ever get there), they have to demonstrate to their clinical partners (the hospitals - which are in the @rse end of Asia BTW) that they can fully fund such a study. They can't right now, not even close. The folks at IMU would have hoped the SP would have been far higher by now but it isn't, so the biggest capital raise this company has ever done by a long margin is on its way and it will have to be done at a big discount - I'm calling 0.5c. Yes folks, that's half a cent which means massive dilution and remember they listed at 1c three years ago! Diabolical outcome for investors and one would have to wonder if it is worth pursuing at all. Complete and total mismanagement by the Directors and in particular the founder and Executive Chairman, Mr Paul Hopper.